Adverse effects |
| Group A (n = 20) | Group B (n = 20) | p value |
Nausea | 6 weeks | 2 (10.0%) | 14 (70.0%) | <0.001* |
12 weeks | 3 (15.0%) | 19 (95.0%) | <0.001* | |
Vomiting | 6 weeks | 1 (5.0%) | 4 (20.0%) | 0.151 |
12 weeks | 1 (5.0%) | 18 (90.0%) | <0.001* | |
Abdominal pain | 6 weeks | 0 (0.0%) | 1 (5.0%) | 0.311 |
12 weeks | 0 (0.0%) | 3 (15.0%) | 0.072 | |
Restlessness | 6 weeks | 0 (0.0%) | 1 (5.0%) | 0.311 |
12 weeks | 0 (0.0%) | 6 (30.0%) | 0.008* | |
Crying | 6 weeks | 0 (0.0%) | 3 (15.0%) | 0.072 |
12 weeks | 0 (0.0%) | 11 (55.0%) | <0.001* | |
Irritability | 6 weeks | 0 (0.0%) | 1 (5.0%) | 0.311 |
12 weeks | 0 (0.0%) | 5 (25.0%) | 0.017* | |
Refusal to MTX | 6 weeks | 0 (0.0%) | 1 (5.0%) | 0.311 |
12 weeks | 0 (0.0%) | 2 (10.0%) | 0.147 |